
Timber Pharmaceuticals, Inc.
AMEX:TMBR
0.34 (USD) • At close November 27, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Timber Pharmaceuticals, Inc. |
Symbool | TMBR |
Munteenheid | USD |
Prijs | 1.461 |
Beurswaarde | 5,014,890 |
Dividendpercentage | 0% |
52-weken bereik | 1.2 - 3.39 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. John Koconis M.B.A. |
Website | https://www.timberpharma.com |
An error occurred while fetching data.
Over Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)